Vedanta Biosciences

63 articles about Vedanta Biosciences

• Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference

  6/8/2022

  Vedanta Biosciences a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences, will participate in a fireside chat at the JMP Securities Life Sciences Conference being held June 15-16, 2022 at the Lotte New York Palace in New York, NY.

• Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting

  5/24/2022

  Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, announced the details of three podium presentations of research informed by multiple clinical studies at Digestive Disease Week 2022, being held both virtually and in person in San Diego, CA on May 21-24.

• Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results

  4/13/2022

  Vedanta Biosciences, a leading clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, today announced the publication in the journal Cell Host & Microbe of the results from a Phase 1a/1b study evaluating the safety, tolerability, and colonization dynamics of VE303 in healthy adults.

• Vedanta Biosciences to Present at Chardan’s 2022 Metagenomics and Microbiome Medicines Summit

  2/23/2022

  Vedanta Biosciences today announced that Bernat Olle, Ph.D., chief executive officer of Vedanta Biosciences, will participate in a panel and present at the virtual Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022.

• Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary

  10/14/2021

  Vedanta Biosciences today announced the appointment of Simona Levi, Ph.D., J.D., as Chief Legal Officer and Corporate Secretary.

• Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

  10/5/2021

  Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

• 

  Money on the Move: July 21 – 27, 2021

  7/28/2021

  A quick overview of life science companies scooping up some summer spending money this week.

• Vedanta Biosciences Completes $68 Million Series D Financing

  7/21/2021

  Vedanta Biosciences, Inc., a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, announced the closing of a $68 million Series D financing and provided a pipeline update.

• Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)

  6/29/2021

  Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, today announced additional results from a Phase 1 study in healthy volunteers of VE202, the Company’s 16-strain live biotherapeutic product (LBP) candidate for inflammatory bowel disease (IBD).

• Vedanta Biosciences to Present at the SVB Leerink Biopharma Private Company Connect Event

  4/29/2021

  Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using rationally defined bacterial consortia manufactured from clonal cell banks, today announced that members of its management team will participate in the SVB Leerink Biopharma Private Company Connect Event being held virtually Thursday, May 6 - Friday, May 7, 2021.

• Vedanta Biosciences to Present at the 2021 Jefferies Virtual Microbiome-Based Therapeutics Summit

  4/15/2021

  Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using rationally defined bacterial consortia manufactured from clonal cell banks, today announced that Bernat Olle, PhD, Vedanta’s Chief Executive Officer, will participate in the Executive Perspectives on Current Challenges and Opportunities for Microbiome-Based Therapeutics Panel and give a formal presentation

• Vedanta Biosciences to Present at Upcoming Investor Conferences

  3/2/2021

  Vedanta Biosciences , a leading clinical-stage microbiome company developing a new category of oral therapies using rationally defined bacterial consortia manufactured from clonal cell banks, today announced that members of its executive team will present and host one-on-one meetings at the following virtual investor conferences: Chardan 3rd Annual Microbiome Medicines Summit Date: Monday, March 8, 2021

• Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer

  2/8/2021

  Vedanta Biosciences , a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human microbiome-derived bacteria, today announced the appointment of Mark Mullikin as Chief Financial Officer.

• Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors

  11/24/2020

  Vedanta Biosciences , a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced the appointment of Troy Ignelzi as an independent member of its Board of Di

• Vedanta Biosciences Announces Additional Pharmacokinetics Data From Phase 1 Study of VE202 for Inflammatory Bowel Disease to Be Presented at United European Gastroenterology Week 2020

  10/12/2020

  Phase 1 development partner Janssen to present data showing VE202 microbiome-derived bacterial strains rapidly, abundantly and durably colonize the gut of healthy volunteers CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Vedanta Biosciences , a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced that additional pharmacoki

• Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients

  9/30/2020

  Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients Award is first-ever by BARDA directed to advance development of a microbiome drug CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Vedanta Biosciences , a clinical-stage company developing a new category of therapies for immune-mediated di

• Vedanta Biosciences Announces the Appointment of Jeffrey Silber, M.D. as Chief Medical Officer

  9/16/2020

  Veteran IP attorney Nancy Chiu Wilker, Ph.D., J.D., joins leadership team as vice president of legal Company also secured $15 million from Oxford Finance to further support pipeline development

• Vedanta Biosciences Announces Positive Topline Data from Two Phase 1 Studies of VE202, a Rationally Defined Bacterial Consortium Being Advanced for Inflammatory Bowel Diseases (IBD)

  6/9/2020

  VE202 was generally safe and well-tolerated in healthy volunteers, with durable and dose-dependent colonization that will inform the Phase 2 dose regimen

• Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate VE800 In Combination with Bristol-Myers Squibb's Opdivo® (Nivolumab)

  12/10/2019

  First clinical study of a rationally-defined bacterial consortium (VE800) for the treatment of cancer

• Vedanta Biosciences Awarded $5.8 Million CARB-X Grant to Accelerate Development of VE707 for Multi-Drug Resistant Infections

  12/5/2019

  Vedanta Biosciences eligible for an additional $3.5 million upon completion of certain milestones